Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Summary Small-cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse primary sites that lack effective treatments. Using chemical genetic screens, we identified inhibition of ataxia telangiectasia and Rad3-related (ATR), primary activator of the replication stress response, and topoisomerase I (TOP1), nuclear enzyme that suppresses genomic instability, as synergistically cytotoxic in small cell lung cancer (SCLC). In a proof-of-concept study, we combined M6620 (berzosertib), first-in-class ATR inhibitor, and TOP1 inhibitor topotecan in patients with relapsed SCNCs. Objective response rate among patients with SCLC was 36% (9/25), achieving the primary efficacy endpoint. Durable tumor regressions were observed in patients with platinum-resistant SCNCs, typically fatal within weeks of recurrence. SCNCs with high neuroendocrine differentiation, characterized by enhanced replication stress, were more likely to respond. These findings highlight replication stress as a potentially transformative therapeutic SCNC vulnerability, paving the way for rational patient selection in these cancers, now treated as a single disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440 · cited 1×
“ssGSEA enrichment scores were computed using the GSVA R/ Bioconductor package(Hanzelmann et al., 2013) and gene sets obtained from MSigDB.”
MethodMolecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“DNA damage resulting from unabated replication – referred to as DNA replication stress – is a major source of genomic instability in cancers and precancerous lesions (Bartkova et al., 2005; Bartkova et al., 2006; Gorgoulis et al., 2005; Zeman and Cimprich, 2014).”
BackgroundCauses and consequences of replication stress
Zeman, M. K., & Cimprich, K. A. (2014) · Nature Cell Biology · doi:10.1038/ncb2897 · Cited by 2,079 · cited 16×
“S5I, J, Table S2) demonstrated that M6620 blocks irinotecan induced pCHK1 in a dose- and time-dependent manner.”
BackgroundInfluentialActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · cited 1×
“DNA damage resulting from unabated replication – referred to as DNA replication stress – is a major source of genomic instability in cancers and precancerous lesions (Bartkova et al., 2005; Bartkova et al., 2006; Gorgoulis et al., 2005; Zeman and Cimprich, 2014).”
BackgroundOncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“DNA damage resulting from unabated replication – referred to as DNA replication stress – is a major source of genomic instability in cancers and precancerous lesions (Bartkova et al., 2005; Bartkova et al., 2006; Gorgoulis et al., 2005; Zeman and Cimprich, 2014).”
BackgroundAn Oncogene-Induced DNA Damage Model for Cancer Development
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851
Reijns, M. A. M., Rabe, B., Rigby, R. E., Mill, P., Astell, K. R., Lettice, L. A., Boyle, S., Leitch, A., Keighren, M., Kilanowski, F., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.011 · Cited by 466
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465 · cited 4×
“They exhibit ubiquitous loss of tumor suppressors, frequently amplify and overexpress oncogenes such as MYC, and have high expression of lineage transcription factors (Beltran et al., 2016; Chang et al., 2018; George et al., 2015; Semenova et al., 2015), all of which contribute to replication stress (Halazonetis et al…”
BackgroundInfluential
Cited by
Targeting DNA damage response pathways in cancer
Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N., & Tarsounas, M. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00535-5 · Cited by 836
Metadata
- Authors
- Thomas, A., Takahashi, N., Rajapakse, V. N., Zhang, X., Sun, Y., Ceribelli, M., Wilson, K. M., Zhang, Y., Beck, E., Sciuto, L., Nichols, S., Elenbaas, B., Puc, J., Dahmen, H., Zimmermann, A., Varonin, J., Schultz, C. W., Kim, S., Shimellis, H., Desai, P., Klumpp-Thomas, C., Chen, L., Travers, J., McKnight, C., Michael, S., Itkin, Z., Lee, S., Yuno, A., Lee, M.-J., Redon, C. E., Kindrick, J. D., Peer, C. J., Wei, J. S., Aladjem, M. I., Figg, W. D., Steinberg, S. M., Trepel, J. B., Zenke, F. T., Pommier, Y., Khan, J., & Thomas, C. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 39
- Issue
- 4
- Pages
- 566-579.e7
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3154101159
- Cited by
- 173
- References
- 18
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.